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Small heterodimer partner (SHP; NR0B2) is an un-
usual orphan nuclear receptor that lacks a conventional
DNA-binding domain and acts as a modulator of tran-
scriptional activities of a number of nuclear receptors.
Herein, we report that the human SHP promoter (hSHP)
is activated by sterol regulatory element-binding pro-
tein-1 (SREBP-1), which regulates the expression of var-
ious genes involved in cholesterol and fatty acid synthe-
sis. Overexpression of SREBP-1 activated the human but
not mouse SHP promoter, although SREBP-2 had little
effect on the SHP promoter in CV-1 cells. Serial deletion
reporter assays revealed that SREBP-1-responsive re-
gion is located within the sequences from 243 to 120
bp in the hSHP promoter. DNase I footprinting, gel shift
assays, and chromatin immunoprecipitation assays
demonstrated that SREBP-1 binds directly to the hSHP
promoter. Site-directed mutagenesis made it clear that
the hSHP promoter activation by SREBP-1 is mostly
mediated by the SRE1 (186 to 195 bp) in the hSHP
promoter, which is not conserved in the mouse SHP
promoter. Moreover, adenovirus-mediated overexpres-
sion of SREBP-1c/ADD-1 induced SHP mRNA expression
and repressed CYP7A1 expression in HepG2 cells. Fi-
nally, we found that a four-nucleotide deletion (195CT-
GAdel) in the hSHP promoter, which is reported to be
associated with altered body weight and insulin secre-
tion in human, coincides with the SRE1. This mutation
strongly decreased both basal and SREBP-1 dependent
activities of the hSHP promoter, because of the reduced
binding of SREBP-1 to the mutated SRE1. Overall, our
results demonstrate a differential regulation of human
and mouse SHP promoters by SREBP-1. We propose a
possible role of SREBP-1 in the species differential reg-
ulation of cholesterol and bile acid homeostasis via a
novel mechanism of up-regulation of the hSHP gene
expression.
Small heterodimer partner (SHP; NR0B2)1 is a member of
the large nuclear receptor family of transcriptional factors that
lacks a conventional DNA binding domain (1). Various studies
have reported SHP to be a repressor of transcriptional activi-
ties of a number of nuclear receptors, including glucocorticoid
receptor, estrogen receptor, thyroid hormone receptor, retinoic
acid receptor, retinoid X receptor, constitutive androstane re-
ceptor, pregnane X receptor, HNF4, liver receptor homologue
1, estrogen-related receptor-, and liver X receptor (LXR) (2–
10). The very broad range of receptors sensitive to inhibition by
SHP suggests a central role for SHP in modulation of nuclear
receptor signaling pathways. Although the mechanisms under-
lying this repressor function remain unclear, recent results
demonstrate that SHP can compete with coactivators for bind-
ing to the AF-2 surface (7, 11). In addition, a direct transcrip-
tional repression domain contributes significantly to the inhib-
itory function of SHP. SHP is expressed in a wide variety of
tissues, including heart, brain, liver, spleen, adrenal gland,
small intestine, and pancreas (2, 12). The human SHP gene is
located on chromosome 1p36.1 and consists of two exons sepa-
rated by an intron (13). SHP gene transcription is regulated by
several members of the nuclear receptor superfamily, including
the bile acid receptor farnesoid X receptor (14–16), steroido-
genic factor-1 (17), HNF4 (18), liver receptor homologue 1
(14), and estrogen-related receptor- (9). However, other fam-
ilies of transcription factors that can regulate the SHP gene
expression have not yet been fully characterized.
Previous reports have suggested that SHP plays a pivotal
role in the regulation of cholesterol homeostasis via bile acid-
activated regulatory cascade in the liver (14–16). The farnesoid
X receptor-mediated SHP gene induction has been shown to
inhibit the activity of orphan nuclear receptor liver receptor
homologue 1, a positive regulator of cholesterol 7-hydroxylase
(CYP7A1) gene expression, which is a rate-limiting enzyme in
bile acid biosynthesis. LXR, which is activated by metabolites
of cholesterol, has been shown to activate the mouse and rat
but not human CYP7A1 gene promoters by direct binding to
conserved LXR response element, was lacking in human
CYP7A1 promoter (19–21). More recently, LXR has been
shown to induce human but not rat SHP gene expression via
direct binding to the LXR response element in human SHP
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promoter (22), which in turn represses CYP7A1 gene expres-
sion. This report gives another example of the interspecies
difference in the regulation of CYP7A1 gene expression. How-
ever, loss-of-function studies of SHP demonstrated that redun-
dant pathways independent of the SHP-mediated pathway are
implicated in the negative feedback regulation of bile acid
production (23, 24). In addition, it was reported previously that
mutations in the coding region of SHP gene are associated with
mild hyperinsulinemia, moderate obesity, and decreased insu-
lin sensitivity in human (12). However, a recent report has
shown that genetic variations in the SHP gene are unlikely to
be predisposed to diabetes, obesity, or increased birth weight
(25). In addition, it is reported that homozygous mutation
(195CTGAdel) in the SHP gene promoter may be associated
with lower birth weight and insulin secretion in human (26).
Sterol regulatory element-binding proteins (SREBPs) are a
family of membrane-bound transcription factors that regulate
cholesterol and fatty acid homeostasis (27, 28). In mammals,
three SREBP isoforms have been identified that are designated
SREBP-1a, SREBP-1c/ADD1, and SREBP-2. SREBP-1a and
SREBP-1c/ADD1 are derived from the same gene by virtue of
alternative splicing of the first exon (27). SREBP-1a has a
longer transcription-activating domain and is a more potent
transcriptional activator than SREBP-1c in cultured cells and
liver (29). Nascent SREBPs reside in the endoplasmic reticu-
lum and the nuclear envelope as precursor forms (27). The
transcriptionally active amino-terminal segments (mature
forms) are released from the precursor SREBPs by a sequential
two-step cleavage process. Once cleaved, the mature forms
translocate into the nucleus, where they bind to sterol regula-
tory elements (SREs) in the promoters of target genes.
SREBPs regulate the transcription of many genes involved
in cholesterol and fatty acid synthesis, such as low density
lipoprotein (LDL) receptor, farnesyl-pyrophosphate synthase,
squalene synthase, hydroxymethylglutaryl-CoA reductase, hy-
droxymethylglutaryl-CoA synthase, fatty acid synthase, acetyl-
CoA carboxylase and ATP citrate-lyase (30–35). Previous re-
ports suggested that SREBP-1 and SREBP-2 have different
effects on their target genes. SREBP-1 preferentially activates
the genes involved in fatty acid synthesis (36) and SREBP-2
activates genes involved in cholesterol synthesis (37). In addi-
tion, the reports that the SREBP-1c promoter is a direct target
for regulation by LXR/retinoid X receptor heterodimers pro-
vided a straightforward explanation for the ability of LXR
ligands to induce hepatic lipogenesis (38–40). Efficient tran-
scriptional activation by SREBPs is dependent on additional
transcription factors such as nuclear factor Y (NF-Y) and Sp1
(41, 42). Most SREBP target genes require NF-Y binding to
adjacent CCAAT motifs, which are usually located within 21 bp
of the SRE (43). In vitro studies initially demonstrated that the
binding of NF-Y to DNA enhanced the binding affinity of
SREBP to adjacent SREs (31), presumably as a result of direct
interaction of the two proteins (34). Study of the LDL receptor
promoter demonstrated that Sp1 also interacts with SREBP to
form a more stable DNA-protein complex (42, 44).
In this study, we demonstrate that SREBP-1, but not
SREBP-2, stimulates the hSHP promoter through its binding to
SRE1, which is located in the region from186 to195 bp in the
hSHP promoter but is not conserved in the mouse SHP promoter.
We also found that a naturally occurring mutation (195CT-
GAdel) in the hSHP promoter, corresponding to SRE1 mutation,
results in the complete loss of activation by SREBP-1 because of
the reduced binding of SREBP-1 to the altered SRE1. In addition,
adenovirus-mediated overexpression of SREBP-1c/ADD1 re-
pressed CYP7A1 expression by induction of SHP expression in
HepG2 cells. Our results suggest that SREBP-1 can be involved
in the species differential regulation of CYP7A1 gene expression
via direct stimulation of the hSHP promoter.
EXPERIMENTAL PROCEDURES
Plasmids and DNA Construction—SREBP expression plasmids
pCSA10, pCMVhSREBP-1c 436, pCS2, and p5xSRE-tk/Luc were de-
scribed previously (35), and the cDNA encoding SREBP-1c/ADD1–403
for adenovirus recombinant was described previously(45). The wild-
type and mutant reporter plasmids of the hSHP promoter were cloned
into the pGL2-basic plasmid (Promega) using restriction enzymes and
specific primers. Wild-type and serial deletion constructs were made by
fusing various length of 5-flanking sequences of the hSHP promoter to
the luciferase gene at 30 (2.2 kb/Luc, 574 bp/Luc, 355 bp/Luc,
243 bp/Luc, and 120 bp/Luc). Mutant reporters mE-box/Luc,
mSRE1/Luc, mSRE2/Luc, mSRE1,2/Luc, mCCAAT/Luc, and mSp1/Luc
were constructed by introducing site-directed mutagenesis into the
hSHP promoter 355 bp/Luc using the primers. 195CTGAdel/Luc
was made from the 574 bp/Luc by using primers. The mutated se-
quences are shown in Figs. 4A and 7A. SRE1 multi-copy reporters,
hSHP(SRE1)x2, hSHP(SRE1)x3, and hSHP(SRE1)x4/Luc were con-
structed by inserting 2, 3, and 4 copies, respectively, of SRE1 fragments
into the XhoI-digested pGL2-promoter plasmid (Promega). The primers
used to construct SRE1 multi-copy reporters were as follows: 5-TCG-
AGACTGAGGTGATATCAG-3 and 5-TCGACTGATATCAC CTCAGT-
C-3. SRE1-CCAAT/Luc, SRE1/Luc, and CCAAT/Luc reporters were
constructed by inserting a single copy of double-stranded oligonucleo-
tides into the XmaI- and XhoI-digested pGL2-promoter plasmid. The
sequences of the oligonucleotides were as follows: SRE1-CCAAT, 5-
CCGGGACTGAGGTGATATCACAGCTGCCCAATGCCC-3; SRE1, 5-
CCGGGACTGAGGTGATATCAC-3; and CCAAT, 5-CCGGGCCCAAT-
GCCC-3. pcDNA3/HA-ADD1 was constructed by inserting a PCR frag-
ment encoding the N terminus (403 amino acids) of SREBP-1c/ADD1
into EcoRI- and XhoI-digested pcDNA3/HA vector.
Preparation of Recombinant Adenovirus—The recombinant adenovi-
rus was prepared as described previously (46). In brief, the cDNA
encoding SREBP-1c/ADD1–403 was cloned into pAd-YC2 shuttle vec-
tor, which is under the control of the cytomegalovirus promoter and
contains bovine growth hormone polyadenylation signal sequence. For
homologous recombination, pAd-YC2 shuttle vector (5 g) and a rescue
vector, pJM17 (5 g), were cotransfected into human embryonic kidney
293 cells. To purify pure plaques, cell culture supernatant was serially
diluted in serum-free media and incubated with 293 cells at 37 °C for
1 h. An equal volume mixture of 2 medium and 1% agarose was
overlaid on 293 cells. After 7 days, plaques that were well isolated were
further purified and propagated in 293 cells and screened by PCR using
upstream primers derived from the cytomegalovirus promoter and
downstream primers from the bovine growth hormone polyadenylation
sequence. Then, the recombinants were amplified in 293 cells and were
purified and isolated using CsCl2 (Sigma). The preparations were col-
lected and desalted, and titers were determined by the measurement of
plaque counts.
Cell Culture and Transient Transfection Assay—HepG2 and CV-1
cells were maintained with Dulbecco’s modified Eagle’s medium (In-
vitrogen), supplemented with 10% fetal bovine serum (Cambrex Bio
Science Walkersville, Inc., Walkersville, MD) and antibiotics (Invitro-
gen). Cells were split onto 24-well plates at densities of 2–8  104
cells/well the day before transfection. Transient transfection assays
were performed using the SuperFect transfection reagent (Qiagen) ac-
cording to the manufacturer’s instructions. Cells were transfected with
0.2 g of various reporters together with 0.2 g of the SREBP expres-
sion vectors pCSA10, pCMVhSREBP-1c 436, and pCS2. Total DNA
used in each transfection was adjusted to 1 g/well by adding appro-
priate amount of pcDNA3 empty vectors, and 0.2 g of cytomegalovirus-
-galactosidase plasmids were cotransfected as an internal control.
Cells were harvested 40–48 h after the transfection for luciferase and
-galactosidase assays. The luciferase activity was normalized by -ga-
lactosidase activity.
DNase I Footprinting Assay—DNA fragment covering the region
from 355 to 120 bp was labeled in one strand by PCR with a primer
set, one of which was labeled with 32P. The sequences of the primers for
PCR were 5-CCGCTCGAGCGGGCACCAATGGGG-3 and 5-CCCCT-
GGCAGGAATG-3. Recombinant SREBP-1 proteins (1, 2, and 4 g),
purified as described in Ref. 35, were incubated with 3  105 cpm of
labeled probe for 20 min on ice under the condition of 10 mM HEPES,
pH 7.9, 60 mM KCl, 1 mM EDTA, 1 mM dithiothreitol, 7% (v/v) glycerol,
and 2 g of poly(dI-dC), and then 50 l of diluted DNase I solution
(0.002–0.001 units/l) was added to the DNA-protein binding reactions.
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After 2 min of digestion at room temperature, the reaction was stopped
by adding 100 l of stop buffer containing 1% (w/v) SDS, 200 mM NaCl,
20 mM EDTA, pH 8.0, and 0.1 g/l glycogen. The DNA was extracted
with phenol/chloroform and recovered by ethanol precipitation. The
pellets were dissolved in sequencing gel loading buffer and then re-
solved on denaturing 6% polyacrylamide/6 M urea gel. The footprints
were compared with G  A ladder produced by the chemical cleavage
sequencing reaction of the same probe to determine the corresponding
nucleotide sequences.
Gel Mobility Shift Assay—The probes used in gel shift assay cover
the region from 203 to 163 bp of the hSHP promoter. Mutated
sequences are shown in Figs. 4A and 7A as indicated. Double stranded
oligonucleotides were end-labeled with [-32P]ATP using T4 polynucle-
otide kinase. The labeled probes were incubated with 1 g of purified
recombinant SREBP-1a (Fig. 4B) or 1–4 l of in vitro translated
SREBP-1a proteins (Fig. 7, C and D) in 20 l of each reaction containing
10 mM HEPES, pH 7.6, 75 mM KCl, 1 mM EDTA, 10 mM dithiothreitol,
10% (v/v) glycerol, 1 g of poly (dI-dC), and 0.5% bovine serum albumin.
In vitro-translated SREBP-1a proteins were prepared by using a cou-
pled transcription and translation system (TNT-coupled reticulocyte
lysate system; Promega) according to the manufacturer’s instructions.
For unlabeled competition assays, unlabeled oligonucleotides were
added to the reactions at100-fold molar excess (Fig. 4B) or 10, 50, and
100-fold molar excess (Fig. 7D). After a 20-min incubation at room
temperature, the samples were resolved on a 4% polyacrylamide gel in
1 TBE (45 mM Tris, 45 mM boric acid, and 1 mM EDTA) at 250 V for
1 h at room temperature. After electrophoresis, the polyacrylamide gel
was dried and exposed to Fuji HR-G30 X-ray film for 3 h at70 °C with
intensifying screen.
Chromatin Immunoprecipitation Assay—The chromatin immunopre-
cipitation assay was performed as described previously (47). In brief,
HepG2 cells were transfected with 10 g of pcDNA3/HA-SREBP-1c/
ADD1 and pcDNA3/HA empty vectors. At 30 h after transfection, the
cells were fixed with 1% formaldehyde and harvested. For immunopre-
cipitation, anti-HA antibodies (Roche Molecular Biochemicals) and pro-
tein A-Sepharose beads CL-4B (Amersham Biosciences) were used. The
final DNA extractions were amplified by PCR using pairs of primers.
The primers used for PCR were as follows: 120/474 bp, 5-CCCCT-
GGCAGGAATG-3 and 5-AGGTTAGGCAAACAAGC-3; and 880/
1200 bp, 5-CAGCTACTCTAGAGGCTA-3 and 5-CATAAAGTAA-
GAATCTAG-3. The PCR products were a 354-bp fragment (nucleotides
120 to 474 bp of the hSHP promoter) containing SREBP-1 response
region (243 and 120 bp) and a 320-bp fragment (nucleotides from
880 to 1200, used as a negative control).
Northern Blot and Reverse Transcriptase PCR Analyses—HepG2 cells
were maintained with Dulbecco’s modified Eagle’s medium supplemented
with 10% fetal bovine serum for 24 h and infected with 1 ml of adenovirus-
containing Dulbecco’s modified Eagle’s medium at a titer of 100 plaque-
forming units/cell for 12 h at 37 °C. Then, culture medium was adjusted to
2 ml with Dulbecco’s modified Eagle’s medium supplemented with 10%
fetal bovine serum. After viral infection for 0, 3, 6, 12, and 24 h, infected
cells were harvested for RNA isolation using the TRIzol reagent (Invitro-
gen). Northern blot analysis was carried out as described previously (13).
The mRNAs of hSHP and hCYP7A1 were analyzed by RT-PCR as de-
scribed previously (22). In brief, first-strand cDNA was synthesized from
1 g of total RNA using an anchored oligo(dT) primer and reverse tran-
scriptase. The resulting first-strand cDNA was then amplified to measure
mRNA levels of SHP, CYP7A1, and -actin by 25, 30, and 25 cycles of
PCR, respectively, using specific primers. The mRNA levels of -actin
served as an internal control for the RT-PCR analysis. The primers used
for PCR were as follows: SHP forward primer, 5-CAAGAAGATTCTGCT-
GGAGG-3; SHP reverse primer, 5-GGATGT CAACATCTCCAATG-3;
CYP7A1 forward primer, 5-CTAAGGAGGATTTCACTTTGC-3, CYP7A1
reverse primer, 5-ACTGGTCCAAAGGTGGACAT-3; -actin forward
primer, 5-GT CATCACCATTGGCAATGAG-3; and -actin reverse
primer, 5-CGTCATACTCCTGCTTGCTG-3. The sizes of the SHP,
CYP7A1, and -actin in PCR products were 390, 350, and 350 bp,
respectively.
RESULTS
Identification of SREBP-1 as Transcriptional Activators of
the Human SHP Promoter—In an effort to identify the tran-
scription factors that regulate the SHP promoter, we found
putative binding sites for SREBPs (two SREs), NF-Y (CCAAT
box), and Sp1 (GC box) in the human SHP (hSHP) promoter
region spanning from upstream 572 bp to downstream 28
bp of the putative transcription start site (Fig. 1A). We aligned
the sequences containing putative SREs in the human and
mouse SHP (mSHP) promoters and noticed that mouse puta-
tive SRE1 differs from human and consensus SRE sequences,
whereas both human and mouse SRE2/E-box are identical in
the core E-box (Fig. 1B). To determine whether SREBPs regu-
FIG. 1. Putative SREBP regulatory
elements (SREs) on the SHP pro-
moter. A, human SHP promoter se-
quences from 572 to 28 relative to the
putative transcription start site. The gua-
nine at the transcription start site and
TATA-box are designated 1 and TATA-
box, respectively. Underlined nucleotide
sequences indicate the transcriptional
regulatory elements previously identified
to be regulated by HNF4, steroidogenic
factor-1 (SF-1), farnesoid X receptor
(FXR), LXR, activator protein 1 (AP-1),
and estrogen-related receptor- (ERR).
Putative SREs and potential binding sites
for NF-Y and Sp1 are lined above the
respective sequences. B, sequence align-
ment of SRE1 and SRE2 within the hu-
man and mouse SHP promoters. The
numbers indicate the nucleotide posi-
tions:186 to195 bp and125 to224
bp in human and mouse SRE1, respec-
tively; 160 to 179 bp and 199 to
208 bp in human and mouse SRE2/E-
box, respectively.
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late SHP promoter, we performed transient transfection assay
using the reporter gene containing 2.2 kb of the human and
mouse SHP promoters. The p5xSRE-tk/Luc reporter, which
contains five copies of SRE elements from the LDL receptor
gene promoter at the upstream of herpes simplex thymidine
kinase promoter, was used as a positive control. Overexpres-
sion of both pCSA10 and pCMVhSREBP1c 436 encoding the
mature form of human SREBP-1a and -1c strongly activated
the hSHP promoter in CV-1 cells. It is interesting that neither
SREBP-1a nor SREBP-1c activated the mSHP promoter, im-
plying that the difference in SRE1 sequence between human
and mouse SHP promoter might result in the differential reg-
ulation of human and mouse SHP promoter by SREBP-1. It
was noteworthy that SREBP-2 had no significant effect on
either human or mouse SHP promoter activity, whereas
SREBP-2 activated the p5xSRE-tk/Luc activity, as reported
FIG. 2. SREBP-1 transactivates hu-
man but not mouse SHP promoter. A,
transcriptional activation of the hSHP
promoter by SREBP-1 but not by
SREBP-2. CV-1 cells were transiently
transfected with 200 ng of 2.2-kb hu-
man (black bars), mouse SHP promoter
(white bars) fused to a luciferase reporter
or p5xSRE-tk/Luc (gray bars), together
with 100 ng of SREBP expression
plasmids pCSA10 (SREBP-1a), pCMVh-
SREBP-1c 436 (SREBP-1c), pCS2
(SREBP2), or empty vector. B, schematic
diagram of the hSHP promoter deletion
constructs cloned in pGL2-basic vector.
The restriction enzyme and primer sites
used to make the deletions are indicated
at the top. C, mapping the sequences re-
quired for activation of the hSHP pro-
moter by SREBP-1. CV-1 cells were trans-
fected with 200 ng of each reporter
plasmid and 100 ng of SREBP expression
plasmid as indicated. Approximately 40 h
after transfection, the cells were har-
vested and luciferase activity was meas-
ured and normalized against -galacto-
sidase activity. One representative
experiment is shown. All values represent
the mean of duplicate samples, and simi-
lar results were obtained in at least three
independent experiments. The represent-
ative results were expressed as -fold acti-
vation (n-fold) over the value obtained
with vector alone with the error bars as
indicated.
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previously (Fig. 2A). This result indicates that the hSHP gene
is a specific target of SREBP-1 but not of SREBP-2, supported
by the previous reports that SREBP-1 and SREBP-2 have
different effects on their target genes (36, 37). Taken together,
our results suggest that human and mouse SHP promoter can
be differentially and specifically regulated by SREBP-1. To
map the sequences required for SREBP-1-mediated activation,
we made a series of 5 deletions of the hSHP promoter as
indicated in Fig. 2B and performed a transient transfection
assay. As shown in Fig. 2C, SREBP-1 responsiveness was con-
tinuously retained with a deletion up to 243 bp but was lost
with the 120-bp construct. These results indicate that the
sequences required for SREBP-1 response lie in the region
between 243 and 120 bp within the hSHP promoter.
Determination of SREBP-1 Binding Regions by DNase I
Footprinting and Gel Shift Assays—To localize the direct
SREBP-1 binding sites in the region from 355 to 120 bp of
the hSHP promoter containing the SREBP-1 responsive region
(243 to 120 bp), DNase I footprinting assay was performed
using purified recombinant human SREBP-1a proteins ex-
pressed in E. coli (Fig. 3). SREBP-1a protected three regions,
from 160 to 179 (SRE2; designated as SRE2/E-box), from
186 to 195 (SRE1) and from 248 to 267 (designated as
E-box). The inverse sequence (ATCACCTCAG) of SRE1 has
80% homology to SRE (ATCACCCCAC) identified in the LDL
receptor promoter (30). The165 to179 bp (SRE2/E-box) and
248 to 267 bp (E-box) regions correspond to E-box motifs
(CANNTG) that are binding sites for basic helix-loop-helix
proteins. However, the result shown in Fig. 2C suggested that
the upstream E-box (248 to 267 bp) region might not be
necessary for SREBP-1-mediated transactivation of the hSHP
promoter, although SREBP-1 binds to E-box (248 to267 bp)
in DNase I footprinting assay.
To confirm the specific binding of SREBP-1 to these three
footprinted regions, gel shift assays were performed. We de-
signed wild-type (203/163) probes covering the protected
regions (SRE1 and SRE2/E-box) (Fig. 4A). The oligonucleotides
of mutant SRE1 (m1), mutant SRE2/E-box (m2), double mutant
SRE1/SRE2 (m3), wild-type (271/243) containing upstream
E-box, and the E-box mutant (m4) were prepared for unlabeled
competition assay. As shown in Fig. 4B, purified SREBP-1a
proteins produced one major retarded band with wild-type
(203/163) probe (lane 1), although the probe contains two
potential SREs, suggesting that SREBP-1 may bind to only one
of the potential SREs. For competition assay, unlabeled oligo-
nucleotides of203/163, m1, m2, m3,271/243, or m4 were
added to the reactions as competitors. When 100-fold molar
excess of unlabeled oligonucleotides of 203/163 and 271/
243 (lanes 2 and 6) were added, retarded bands almost dis-
appeared. The unlabeled oligonucleotides of m3 and m4 had no
significant effects on the SREBP-1 binding to wild-type (203/
163) probes. However, SREBP-1-DNA complex formation was
slightly inhibited by the excess of unlabeled mutant SRE1 (m1,
lane 3) oligonucleotides, whereas the retarded band almost
disappeared by addition of mutant SRE2/E-box (m2, lane 4)
oligonucleotides. Thus, to exclude the fold excess used as com-
petitors and to directly confirm whether SREBP-1 binds to
individual SRE1 or SRE2 within the203/163 sequences, the
labeled oligonucleotides of m1, m2, or m3 were used as probes
in gel shift assay. The m2 probe, containing intact SRE1, avidly
formed the complex with SREBP-1 comparable with that of
wild probe (lane 9), whereas SRE1 mutation (m1) drastically
inhibited the complex formation (lane 8) and the double muta-
tion of SRE1 and SRE2 completely blocked the binding to
SREBP-1 (lane 10). These results indicated that SREBP-1
binds predominantly to SRE1 and weakly to SRE2/E-box.
To verify that SREBP-1 binds to the hSHP promoter in vivo,
we performed chromatin immunoprecipitation assay using two
sets of PCR primers specific for 120 to 474-bp region con-
taining SREBP-1 responsible region and the primers encom-
passing the 880 to 1200 bp of the hSHP promoter as a
negative control. Expression vectors encoding HA epitope only
or HA-SREBP-1c/ADD1 were transfected into HepG2 cells, and
cell lysates were immunoprecipitated with the anti-HA anti-
body. As shown in Fig. 4C, the 354 bp of PCR product (120 to
474 bp) was observed in cells transfected with expression
vectors for HA-SREBP-1c/ADD1, but not for HA epitope only,
indicating that HA-SREBP-1c/ADD1 formed a specific complex
FIG. 3. Determination of the SREBP-1 binding sites in the
hSHP promoter by DNase I footprinting. The 235-bp DNA frag-
ments of the hSHP promoter (nucleotides 355 to 120) were 32P-
labeled at the end of the sense or antisense strands and then PAGE-
purified. The radiolabeled probes and the purified human recombinant
SREBP-1a expressed in Escherichia coli were used for the reaction. The
preparation of recombinant protein and DNase I footprinting assay was
performed as described under “Experimental Procedures.” DNase I-
treated reaction mixtures were subjected to electrophoresis on denatur-
ing 6% polyacrylamide gel. The same radiolabeled probes were also
subjected to chemical cleavage sequencing reactions (G  A). The reac-
tion products in the lanes were: lanes 1 and 6, G  A reaction; lane 5,
reactions without protein; lanes 2, 3, and 4, reactions with 4, 2, and 1 g
of SREBP-1a, respectively. The protected regions (boxes) and their
relative positions in the hSHP promoter are indicated as SRE1, SRE2,
and E-box.
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with the hSHP promoter in vivo. No bands were detected for
the region spanning 880 to 1200 bp of hSHP promoter used
as a negative control. These results demonstrated that
SREBP-1 binds to the hSHP promoter in vivo. Taken together,
we suggest that SREBP-1 regulates the hSHP promoter by
direct binding to SRE1.
The SRE1 (186 to 195 bp) Plays a Critical Role in the
Transactivation of the hSHP Promoter by SREBP-1—To fur-
ther evaluate the functional significance of the SREBP-1 bind-
ing sites (SRE1, SRE2, and E-box) in the hSHP promoter that
we identified, site-directed mutagenesis was introduced to the
355-bp hSHP promoter using the primers as indicated (Fig.
5A). Wild-type 355 bp/Luc and the mutant reporter plasmids
were transiently transfected with SREBP-1 expression vectors
into HepG2 cells. The SRE1 mutation (mSRE1/Luc) and double
SRE1 and 2 mutation (mSRE1,2/Luc) completely abolished the
SREBP-1 mediated activation of the hSHP promoter (Fig. 5B).
However, SRE2 mutation had little effect on the activation of
the hSHP promoter by SREBP-1, supporting the results from
Fig. 4B showing that SREBP-1 predominantly binds to SRE1
rather than SRE2. In addition, the E-box mutant (mE-box/Luc)
reporter was still activated by SREBP-1. This observation was
consistent with the result from Fig. 2C, showing that the
SREBP-1 responsive region, located between 243 and 120
bp, does not contain the E-box.
The SREBPs have been shown to work efficiently depending
on the promoters along with ubiquitous coregulatory proteins
such as Sp1 (42) or NF-Y (41). To test whether adjacent SRE
related elements (CCAAT box and Sp1 binding site) are in-
volved in SREBP-1-mediated activation of the hSHP promoter,
mutant reporters of CCAAT box (mCCAAT/Luc) and Sp1 bind-
ing site (mSp1/Luc) were constructed by introducing site-di-
rected mutagenesis to 355 bp/Luc. As shown in Fig. 5B,
SREBP-1 dependent reporter activity was significantly de-
creased by mutation of CCAAT box (mCCAAT/Luc), suggesting
that the CCAAT box binding proteins can be involved in the
SREBP-1-dependent activation of the hSHP promoter. How-
ever, mutation of Sp1 binding site had little effect on the
SREBP-1-mediated activation of the hSHP promoter.
To further confirm whether the CCAAT box is directly re-
quired for the ability of SREBP-1 to transactivate the hSHP
promoter, we constructed the reporters, the SRE1/Luc,
CCAAT/Luc, and SRE1-CCAAT/Luc, containing one copy of
individual SRE1, CCAAT box, and both SRE1 and CCAAT box,
respectively, which originated from the hSHP promoter. The
reporters were cotransfected with expression vectors for
SREBP-1a into HepG2 cells. As shown in Fig. 5C, the SRE1/
Luc reporter was significantly activated by SREBP-1a,
whereas SREBP-1a had little effect on either CCAAT/Luc or
the pGL2 basal promoter. SREBP-1-mediated reporter activ-
ity of SRE1-CCAAT/Luc was unexpectedly similar to that of
SRE1/Luc, suggesting that CCAAT box may be indirectly
involved in the ability of SREBP-1 to transactivate the hSHP
promoter in the natural promoter context. To test specifically
whether SRE1 was sufficient to confer SREBP-1 responsive-
ness, we constructed multiple copies of SRE1 reporters con-
taining two, three, or four copies of SRE1 and performed a
transient transfection assay using the reporter genes as in-
dicated (Fig. 5D). SREBP-1a activated multiple copies of
SRE1 as well as p5xSRE-tk reporter from the LDL receptor
gene promoter, whereas SREBP-1a had no effect on the pGL2
basal promoter. These results indicate that SRE1 may be
sufficient to mediate the activation of the hSHP promoter by
SREBP-1. Taken together, we conclude that SRE1 plays a
major role in the activation of the hSHP promoter by
SREBP-1.
Induction of SHP mRNA by SREBP-1c/ADD1 in HepG2
Cells—To examine whether SREBP-1 is directly involved in the
regulation of the hSHP gene expression, we overexpressed
SREBP-1c/ADD1 into HepG2 cells via adenovirus infection. As
shown in Fig. 6A, SHP mRNA was induced by overexpression of
AD-SREBP-1c/ADD1 at 3 h and peaked at 12 h after infection.
FIG. 4. SREBP-1 predominantly
binds to SRE1 in the hSHP promoter
in gel mobility shift assay. A, the se-
quences of wild-type (nucleotides 203 to
163 and 271 to 243) and mutant
(m1, m2, m3, and m4) oligonucleotides
used for the gel retardation assays are
shown as indicated. Lower case letters in-
dicate the substituted nucleotides in the
SRE1, SRE2/E-box, and E-box. B, gel
mobility shift and unlabeled competition
assays were performed with the 32P-
labeled wild-type (lanes 1–7), mutant
(lanes 8–10), probes, and recombinant
SREBP-1a (1 g) protein as indicated.
Unlabeled oligonucleotides were added as
competitors at 100-fold molar excess
where indicated. C, chromatin immuno-
precipitation assay. HepG2 cells were
transfected with expression vectors for
HA epitope only or HA/SREBP-1c/ADD1.
Soluble chromatin from these cells was
prepared and immunoprecipitated with
monoclonal antibody against HA (lanes 3
and 4) as described previously (48). The
474  120 bp fragment (354 bp) con-
tains SREBP-1 binding site and 10% of
the soluble chromatin used in the reaction
was used as inputs (lanes 1 and 2). The
1200  880 bp fragment is used as a
negative control, and 2.2 kb/Luc plas-
mids were amplified as a positive control
(lane 5) as indicated.
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This result suggests that SREBP-1 can stimulate the hSHP
gene promoter in the natural promoter context.
Based on the previous report showing that overexpression of
SHP represses the hCYP7A1 promoter (22), we examined
whether AD-SREBP-1c/ADD1 could repress the transcription
of hCYP7A1 gene via induction of the hSHP gene expression.
RT-PCR analysis was performed to detect CYP7A1 mRNA,
because we could not detect CYP7A1 expression by Northern
blotting in HepG2 cells. RT-PCR results showed that AD-
SREBP-1c/ADD1 induced SHP mRNA expression, consistent
with Northern blot analysis (Fig. 6B). In addition, AD-SREBP-
1c/ADD1 significantly repressed endogenous CYP7A1 mRNA
expression in HepG2 cells, indicating that induction of the
hSHP gene by SREBP-1 may contribute to the repression of
CYP7A1 gene expression. Taken together, these results sug-
gest that SREBP-1 can increase endogenous human SHP
FIG. 6. Adenovirus-mediated SREBP-1c/ADD1 overexpression
stimulated the hSHP mRNA expression in the HepG2 cells.
HepG2 cells were infected with adenoviral vector expressing SREBP-
1c/ADD1 (100 plaque-forming units/cells). Total RNA was isolated from
cells at the indicated time after infection and analyzed by Northern
blotting (A) and RT-PCR (B). A, an RNA blot containing 20 g of total
RNA was hybridized with 32P-labeled probes for SHP. B, the mRNA
levels of SHP, CYP7A1, and -actin were analyzed by RT-PCR.
FIG. 5. The SRE1 (186 to195 bp) plays a critical role in the transactivation of the hSHP promoter by SREBP-1. A, schematic diagrams
of wild-type and mutant hSHP promoter constructs from28 bp to355 bp as indicated. The putative CCAAT box and Sp1 binding site are indicated
by squares and ovals, respectively. B and C, SRE1 is essential for the activation of the hSHP promoter by SREBP-1. HepG2 cells were cotransfected
with 200 ng of wild type or mutant hSHP promoter constructs (B) and SRE1-CCAAT/Luc, SRE1/Luc, and CCAAT/Luc (C) together with 100 ng of
SREBP-1 expression plasmids pCSA10, pCMVhSREBP-1c 436, or empty vectors, as indicated. D, SRE1 is sufficient to confer the SREBP-1 respon-
siveness. HepG2 cells were transfected with 100 ng of multiple copies of SRE1/Luc (two, three, or four copies), p5xSRE-tk or pGL2 promoter together
with 100 ng of SREBP-1 expression plasmids pCSA10 or empty vector. Two days after transfection, cells were harvested for luciferase and
-galactosidase assays. The representative results were expressed as -fold activation (n-fold) over the value obtained with vector alone with the error
bars as indicated.
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mRNA level, which results in the feedback repression of
CYP7A1 gene expression.
Effect of Naturally Occurring Mutation in SRE1 on SREBP-
1-Dependent Activation of SHP Promoter—It has been reported
that mutations in the SHP gene in the Japanese subjects are
associated with mild hyperinsulinemia and obesity (12, 25).
More recently, it is reported that a genetic variation in the
hSHP promoter results in the lower birth weight and insulin
secretion. The 4-bp (CTGA) deletion at 195 bp upstream of
the transcription start site of human SHP promoter (desig-
nated 195CTGAdel) was found in subjects from the UK (26).
We were intrigued to find that 195CTGAdel occurs in the
region corresponding to SRE1, suggesting that the deletion can
affect the SREBP-1-dependent activation. To address this, we
made and transfected a reporter construct (195CTGAdel/
Luc) that harbors CTGA nucleotide deletion from the hSHP
promoter (574bp/Luc). As shown in Fig. 7A, basal activity of
195CTGAdel/Luc was remarkably diminished about 10-fold
less than that of wild-type promoter in HepG2 cells. Further-
more, SREBP-1 responsiveness was almost completely abol-
ished with 195CTGAdel/Luc reporter. This result suggests
that the naturally occurring 195CTGAdel mutation corre-
sponding to SRE1 mutation may have significant effect on
the SREBP-1 mediated transactivation of the hSHP
promoter.
To investigate whether the loss of activation of195CTGAdel/
Luc by SREBP-1 can be at least partly caused by the alteration in
SREBP-1 binding potential to DNA, we performed gel shift assay
using the wild-type (203/163, containing SRE1 and SRE2)
and 195CTGAdel probes (Fig. 7B). SREBP-1a proteins were
prepared by in vitro translation and incubated with the labeled
probes. SREBP-1a binds to WT(203/163) probes, as shown by
retarded complex compared with unprogrammed lysates. How-
ever, SREBP-1a did not show significant binding to the195CT-
GAdel probes (Fig. 7C). This result suggests that no significant
SREBP-1 binding to SRE2 occurs, supported by the result from
Fig. 4B. These results indicate that deletion of 4 bp in SRE1
may result in the reduced SREBP-1 binding to SRE1 in the
hSHP promoter. To confirm the reduced binding affinity of
SREBP-1 to the mutated SRE1, we employed competition
assay using unlabeled oligonucleotides of WT(203/163),
195CTGAdel, and LDLR-SRE as competitors. As shown in
Fig. 7D, unlabeled oligonucleotides of WT (203/163) and
LDLR-SRE (designated SRE) considerably perturbed
SREBP-1a binding to WT(203/163) probes. However, in-
creasing amounts of 195CTGAdel (designated del) oligonu-
cleotides had a modest effect on the SREBP-1 binding to WT
(203/163) probes. Taken together, these observations sug-
gest that the mutation in the hSHP promoter, naturally
occurring in SRE1, may result in the reduction of the hSHP
gene transcriptional activation by SREBP-1.
FIG. 7. Naturally occurring muta-
tion in SRE1 drastically reduced the
hSHP promoter activity and DNA
binding affinity by SREBP-1. A, natu-
rally occurring mutation (195CTGAdel)
in the hSHP promoter abolished the
SREBP-1 dependent activation of the
hSHP promoter. HepG2 cells were trans-
fected with 200 ng of wild type (574bp/
Luc) or mutant type (195CTGAdel/Luc)
hSHP promoter reporter together with
100 ng of expression plasmids encoding
SREBP-1a, SREBP-1c, SREBP2, or
empty vector. Approximately 40 h after
transfection, the cells were harvested,
and luciferase activity was measured and
normalized against -galactosidase activ-
ity. B, the oligonucleotide sequences of
wild-type (nucleotides 203 to 163 con-
taining SRE1 and SRE2) and mutant
(195CTGAdel) probes used for the gel
retardation assay. C, naturally occurring
mutation in the hSHP promoter mark-
edly diminished the binding ability of
SREBP-1 to DNA. 32P-labeled wild type
(203 to 163, lanes 1–6) and 195CT-
GAdel (lanes 7–12) probes were combined
with 1 to 4 l of SREBP-1a proteins pre-
pared by in vitro translation system as
indicated. The total amounts of proteins
used in the reactions were adjusted to 4 l
by adding unprogrammed lysates, except
for lanes 1 and 7. D, for unlabeled compe-
tition assays, 10-, 50-, and 100-fold molar
excess of the unlabeled oligonucleotides
(WT, 195CTGAdel, and LDLR-SRE)
were added to the reaction containing 32P-
labeled wild type SRE1 and in vitro trans-
lated SREBP-1a (2 l), as competitors.
DNA-protein complexes were analyzed on
4% polyacrylamide gel and analyzed by
autoradiography.
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DISCUSSION
Previous reports have identified several nuclear receptors,
such as steroidogenic factor-1, liver receptor homologue-1,
HNF4, farnesoid X receptor, estrogen-related receptor-, and
LXR, as potent regulators of SHP gene expression (9, 14–18,
22). We recently reported that basic helix-loop-helix transcrip-
tion factor E2A and orphan nuclear receptor steroidogenic fac-
tor-1 synergistically activate the human, but not mouse SHP
gene promoter (48). However, whether other families of tran-
scription factors regulate SHP gene transcription has not been
fully characterized. In this report, we have demonstrated that
SREBP-1 is a novel regulator of human SHP gene expression.
It was interesting that SREBP-1 activated the human, but not
the mouse, SHP promoter (Fig. 2A). SRE1 located in 186–
195 bp within the hSHP promoter, which is not conserved in
mouse SHP promoter, is identified as SREBP-1-responsive el-
ement. In addition, we showed that the hSHP promoter was
activated by SREBP-1 but not by SREBP-2. Our finding is
supported by the previous reports suggesting that SREBP-1
and SREBP-2 have different effects on their target genes.
SREBP-1 preferentially activates genes involved in fatty acid
synthesis (36) and SREBP-2 activates genes involved in cho-
lesterol synthesis (37). The mechanism for the differences in
sterol regulation between SREBP-1c and 2 is currently un-
known; however, the relative low sequence homology between
their cholesterol regulatory carboxyl-terminals might be in-
volved (49). In addition, previous reports have suggested that
SREBP-1 and -2 have different binding affinities to SREs in
ATP citrate-lyase promoter (35). However, we could not observe
any difference in the binding affinities of SREBP-1 and -2 to
SRE1 within the hSHP promoter (data not shown). It is still
possible that amino-terminal activation domains of these fac-
tors have different compatibility to the hSHP promoter.
Optimal transcriptional activation by SREBPs depends on
additional transcription factors such as Sp1, NF-Y, cAMP re-
sponse element-binding protein, or CCAAT/enhancer-binding
protein  (41, 42, 45, 50). Activation of SREBP target genes
require NF-Y binding to adjacent CCAAT motifs that are usu-
ally located within 21 bp of the SRE (43). In addition, it has
been demonstrated that SREBP and Sp1 cooperatively trans-
activate the LDL receptor and phosphoenolpyruvate carboxyki-
nase promoters (42, 44, 51). In vitro studies have demonstrated
that the binding of NF-Y or Sp1 to DNA is associated with
synergistic binding of SREBP to an adjacent SRE (31, 42),
presumably as a result of direct protein-protein interaction (34,
44). It is interesting that Sp1 does not seem to be involved in
the SREBP-1-mediated activation of the hSHP promoter (Fig.
5B). We showed that mutation in putative CCAAT box signif-
icantly reduced the activity of the hSHP promoter by SREBP-1.
However, we could observe no significant effect of the domi-
nant-negative form of NF-YA on the SREBP-1 dependent acti-
vation of the hSHP promoter (data not shown), suggesting that
other CCAAT box binding proteins can be implicated in the
SREBP-1 activation. We also showed that the presence of
CCAAT box had little effect on SREBP-1-dependent transacti-
vation of SRE1 (Fig. 5C), suggesting that CCAAT box may be
indirectly involved in SREBP-1 dependent transactivation of
the hSHP promoter in a natural promoter context. However,
the CCAAT box binding proteins associated with the regulation
of the hSHP promoter by SREBP-1 remain to be determined.
It has been reported that a number of factors, including
cholesterol, insulin, glucose, and polyunsaturated fatty acids,
are involved in SREBP-1 gene expression or its nucleus trans-
location. Thus, human SHP promoter is likely to be regulated
by those factors. For example, insulin, an activator of SREBP-1
expression, has been shown to repress the CYP7A gene pro-
moter activity in HepG2 cells (52). The inhibitory effect of
insulin on the human CYP7A gene expression was much stron-
ger than the rat gene. However, little has been studied on the
apparent molecular mechanism of species differences in the
regulation of CYP7A gene by insulin. We found that adenovi-
rus-mediated overexpression of SREBP-1 repressed the
hCYP7A1 gene expression, probably via induction of hSHP
gene in HepG2 cells (Fig. 6B). Therefore, we assume that
SREBP-1 induced by insulin can activate the hSHP promoter,
a negative regulator of CYP7A gene expression and that up-
regulation of hSHP gene by SREBP-1 may provide a molecular
mechanism by which insulin more strongly suppresses the
human CYP7A gene expression than rat gene. In addition, LXR
agonists have been reported to differentially regulate the
CYP7A1 gene expression in human and rat/mouse (53). We
demonstrated that hSHP mRNA is directly activated by over-
expression of SREBP-1c (Fig. 6A), which is a well known target
gene of LXR. Thus, we propose an alternative molecular path-
way in which LXR agonists repress the human CYP7A1 gene
expression via sequential induction of SREBP-1 and SHP gene.
It was previously reported that mutations in SHP gene are
associated with mild hyperinsulinemia and obesity as a result
of impaired inhibition of HNF4 activity, which is known as a
positive regulator of insulin secretion (12). More recently, it
was also reported that SHP gene mutation might not be pre-
disposed to diabetes, obesity, or increased birth weight (25). In
addition, although mutations in SHP are unlikely to be a com-
mon cause of severe obesity, homozygous mutation (195CT-
GAdel) in the SHP gene promoter may influence birth weight,
body mass index, and insulin secretion in human (26). The
195CTGAdel mutation in the SHP gene promoter noticeably
coincides with the SRE1, which we here characterized as an
SREBP-1-responsive element in the hSHP promoter. It is in-
teresting that this mutation caused a significant reduction of
both basal and SREBP-1-dependent activity of the hSHP pro-
moter as a result of reduced binding of SREBP-1 to the mutated
SRE1. Therefore, we suggest that the reduction of SREBP-1
dependent SHP gene expression by SRE1 mutation within the
hSHP promoter may result in lower body weight and insulin
secretion in human. It is necessary to study further the phys-
iological significance between the promoter mutation and the
loss of hSHP gene transactivation by SREBP-1. Furthermore,
the physiological role of SHP induced by SREBP-1 in fatty acid
synthesis or cholesterol synthesis remains to be elucidated and
the occurrence of interspecies differences in those pathways
that might be mediated by SHP remains to be studied.
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